Cargando…

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of CML patients achieving deep and sustained molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loscocco, Federica, Visani, Giuseppe, Ruzzo, Annamaria, Bagaloni, Irene, Fuligni, Fabio, Galimberti, Sara, Di Paolo, Antonello, Stagno, Fabio, Pregno, Patrizia, Annunziata, Mario, Gozzini, Antonella, Barulli, Sara, Gabucci, Elisa, Magnani, Mauro, Isidori, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155509/ https://www.ncbi.nlm.nih.gov/pubmed/34055641 http://dx.doi.org/10.3389/fonc.2021.672287

Ejemplares similares

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
por: Galimberti, Sara, et al.
Publicado: (2017)

Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma
por: Bagaloni, Irene, et al.
Publicado: (2021)

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
por: Hill, Christopher R., et al.
Publicado: (2013)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Third Party Cord Blood Transplant Boosts Autologous Hematopoiesis in a Case of Persistent Bone Marrow Aplasia after Double Transplant Failure for B-Thalassemia Major
por: Visani, Giuseppe, et al.
Publicado: (2013)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis
por: Visani, Giuseppe, et al.
Publicado: (2023)

A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions
por: Szabó, Edit, et al.
Publicado: (2018)

Autologous Stem Cell Transplantation for Aggressive Lymphomas
por: Visani, Giuseppe, et al.
Publicado: (2012)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Treatment options for acute myeloid leukemia patients aged <60 years
por: Visani, Giuseppe, et al.
Publicado: (2022)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
por: Sicuranza, Anna, et al.
Publicado: (2022)

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study
por: Sabet, Ziba, et al.
Publicado: (2022)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine
por: Piatkov, Irina, et al.
Publicado: (2017)

Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients
por: Chiarucci, Martina, et al.
Publicado: (2021)

Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
por: Shen, Tong, et al.
Publicado: (2009)

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines
por: Oba, Takaaki, et al.
Publicado: (2016)

Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort
por: Ulzurrun, Eugenia, et al.
Publicado: (2014)

ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure
por: El Biali, Myriam, et al.
Publicado: (2021)

Correction: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
por: Shen, Tong, et al.
Publicado: (2009)

Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort
por: Ulzurrun, Eugenia, et al.
Publicado: (2015)

Down-regulation of ABCG2 and ABCB4 transporters in the placenta of rats exposed to cadmium
por: Liu, Lili, et al.
Publicado: (2016)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2()
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Genistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells
por: Schexnayder, Chandler, et al.
Publicado: (2015)

An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy
por: Dixon, Peter H., et al.
Publicado: (2017)

Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients
por: Spitzwieser, Melanie, et al.
Publicado: (2016)

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
por: Gardner, Erin R, et al.
Publicado: (2009)

Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme
por: Oberstadt, Moritz C, et al.
Publicado: (2013)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
por: Zhang, Yongchao, et al.
Publicado: (2020)

Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study
por: Caronia, Daniela, et al.
Publicado: (2011)

ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen
por: Sensorn, Insee, et al.
Publicado: (2016)

High ABCC2 and Low ABCG2 Gene Expression Are Early Events in the Colorectal Adenoma-Carcinoma Sequence
por: Andersen, Vibeke, et al.
Publicado: (2015)

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients
por: Bocchia, Monica, et al.
Publicado: (2016)

GENETIC POLYMORPHISMS OF THE ADENOSINE TRIPHOSPHATE-BINDING CASSETTE TRANSPORTERS(ABCG2, ABCB1) AND GEFITINIB TOXICITY
por: TAMURA, MARIKO, et al.
Publicado: (2012)

Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function
por: Atisha-Fregoso, Yemil, et al.
Publicado: (2016)

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
por: Eadie, Laura N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vahlpcj3ko42u46mfth46hrc8d